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Human height is a composite measurement, reflecting the sum of leg, spine, and head lengths. Many common variants influence total
height, but the effects of these or other variants on the components of height (body proportion) remain largely unknown. We studied
sitting height ratio (SHR), the ratio of sitting height to total height, to identify such effects in 3,545 African Americans and 21,590 in-
dividuals of European ancestry. We found that SHR is heritable: 26% and 39% of the total variance of SHR can be explained by common
variants in European and African Americans, respectively, and global European admixture is negatively correlated with SHR in African
Americans (r2z 0.03). Six regions reached genome-wide significance (p < 53 108) for association with SHR and overlapped biological
candidate genes, including TBX2 and IGFBP3. We found that 130 of 670 height-associated variants are nominally associated (p < 0.05)
with SHR, more than expected by chance (p ¼ 5 3 1040). At these 130 loci, the height-increasing alleles are associated with either a
decrease (71 loci) or increase (59 loci) in SHR, suggesting that different height loci disproportionally affect either leg length or spine/
head length. Pathway analyses via DEPICT revealed that height loci affecting SHR, and especially those affecting leg length, show enrich-
ment of different biological pathways (e.g., bone/cartilage/growth plate pathways) than do loci with no effect on SHR (e.g., embryonic
development). These results highlight the value of using a pair of related but orthogonal phenotypes, in this case SHR with height, as a
prism to dissect the biology underlying genetic associations in polygenic traits and diseases.Introduction
Human height has been used extensively as a model
quantitative trait because it is highly heritable and poly-
genic, influenced by variants across many different loci.1
Recently, we and others identified 697 height-associated
variants in a genome-wide association study (GWAS)
of more than 300,000 individuals that together implicated
many genes and pathways important for skeletal growth.2
However, human height is a composite phenotype, reflect-
ing the sum of head, trunk, and leg lengths. Although the
genetics of height has been extensively studied, little is
known about the genetics of the relationship between
these individual components with each other (body pro-
portion). We hypothesize that studying the genetics of
body proportion could provide complementary insights
to those obtained by studying overall height.
Sitting height, the distance from the top of the head to
the seated surface while a person is sitting upright, is a
clinical measurement and sometimes measured in popula-
tion-based studies.3 As such, it is an available measure
that can provide insights into body proportion. Specif-
ically, sitting height ratio (SHR), the ratio of sitting height
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The Amtion: higher SHR corresponds to a higher spine/head to
leg ratio, i.e., shorter leg length. Previous studies character-
izing the SHR of individuals from childhood to adulthood
show that SHR decreases rapidly from birth to teenage
years (from 0.65 to 0.51 between ages 1 and 12 years)
and increases slightly during puberty (from 0.51 to 0.52 be-
tween ages 12 and 18 years).3,4 Combined consideration of
height and SHR can identify effects on height that act
disproportionately on one body segment. For example, in-
dividuals with achondroplasia (MIM 100800) have short
stature due to shortened limbs, reflected in an average
SHR of 0.66 (for comparison, the 95% confidence interval
of normal adult SHR of European-ancestry individuals is
0.51 to 0.55).5,6 On the other hand, individuals with spon-
dyloepiphyseal (MIM 608361) and spondylometaepiphy-
seal (MIM 271665) dysplasias can have short stature but
normal or decreased SHR values.7 SHR can also be indica-
tive of future health outcomes. Previous studies indicate
that SHR can be predictive of several traits and diseases
including blood pressure, cholesterol levels, body mass in-
dex, intimal-medial thickness, type 2 diabetes, and insulin
resistance.8–10
Although little is known about the heritability of SHR,
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ancestries. Adult individuals of African ancestry have lower
SHR (SHR ~ 0.51) than individuals of European ancestry
(SHR ~ 0.52) and individuals of Asian ancestry (SHR ~
0.53).11 The basis of these significant differences in SHR
across populations is unclear.
This lack of knowledge about the genetics of SHR and the
potential to gain new insights into the genetics of skeletal
growth prompted us to investigate the heritability and the
genetic architecture of this trait. We studied a total of 3,545
African Americans as well as 21,590 individuals of Euro-
pean ancestry that had both whole genome genotype
data as well as the phenotypes needed to calculate SHR.
We investigated the heritability and genetic architecture
of SHR by performing several analyses including GCTA-
REML12 to estimate heritability and admixture analysis
and GWAS to identify common variants associated with
SHR. Furthermore, given that we and others have recently
identified many height-associated loci from GWASs,2 we
used SHR like a prism to separate these loci into those
that have an association with SHR and those that do not.
The loci that have an association with SHR can be further
separated into those that disproportionately affect the
head/spine and those that disproportionately affect the
long bones by testing whether the height-increasing allele
increases or decreases SHR, respectively. We tested for
enrichment of biological pathways for the various groups
of loci and found that the loci associated with SHR, espe-
cially those that disproportionately affect the long bones,
are significantly more enriched for genes in well-known
pathways relevant to skeletal growth. On the other hand,
the loci that are least associated with SHR tend to be
more enriched for pathways involved in growth during
embryogenesis. In general, our results highlight the capa-
bility of using an orthogonal phenotype like SHR to sepa-
rate genetic loci known to be associated with height into
their biological relevant components.Material and Methods
Subjects
Individuals were recruited from various cohorts that have
recording of sitting height, height, gender, age when measured,
and body mass index (BMI). If there exists duplicated or closely
related samples (PI_HAT > 0.05), one was randomly filtered out.
Atherosclerosis Risk in Communities
The participants of Atherosclerosis Risk in Communities (ARIC)
study13 were recruited from four communities beginning in
1987: Forsyth County, NC; Jackson, MS; the northwest suburbs
of Minneapolis, MN; and Washington County, MD (dbGaP
phs000280.v3.p1). Whole genome genotyping performed with
the Affymetrix 6.0 platform and genotype calling was performed
with Birdseed calling algorithm.14 2,354 African Americans and
7,257 European Americans were used for the analyses.
Cardiovascular Health Study
The participants of Cardiovascular Health Study (CHS)15 were
recruited from Forsyth County, NC; Sacramento County,
CA; Washington County, MD; and Pittsburgh, PA (dbGaP
phs000287.v4.p1). Whole genome genotyping was performed696 The American Journal of Human Genetics 96, 695–708, May 7, 2with the Illumina HumanCNV370v1 platform and genotype
calling was performed with Illumina GenomeStudio software.
476 African Americans and 2,926 European Americans were used
for the analyses.
Coronary Artery Risk Development in Young Adults
The participants of Coronary Artery Risk Development in Young
Adults (CARDIA) study16 were recruited from four communities
in the United States: Birmingham, AL; Chicago, IL; Minneapolis,
MN; and Oakland, CA (dbGaP phs000285.v3.p2). Whole genome
genotyping performed with the Affymetrix 6.0 platform and geno-
type calling was performed with Birdseed calling algorithm.14 715
African Americans and 1,047 European Americans were used for
the analyses.
Framingham Heart Study
The participants of Framingham Heart Study (FHS)17 were re-
cruited from town of Framingham, MA, starting from 1948
(dbGaP phs000007.v25.p9). Whole genome genotyping was per-
formed by the Affymetrix 500K platform and genotype calling
was performed with Birdseed calling algorithm.14 713 European
Americans were used for the analyses.
The data for ARIC, CHS, CARDIA, and FHS cohorts were ob-
tained from dbGaP (see Acknowledgments).
1958 British Birth cohort
The participants of 1958 British Birth Cohort (B58C)18 were born
in England, Scotland, and Wales during a single week of 1958.
Whole genome genotyping was performed with the Illumina
HumanHap 550K/610K platform and genotype calling was per-
formed with Illumina GenomeStudio software. Genome-wide
typing and imputations were available for 6,296 cohort members
with measurements of standing and sitting height at age 44–45
years.
Avon Longitudinal Study of Parents and Children
We used only the adult mothers from Avon Longitudinal Study of
Parents and Children (ALSPAC) study19 for the analyses. Whole
genome genotyping was performed with Illumina human660W-
quad array platform and genotype calling was performed with
Illumina GenomeStudio software. A total of 3,351 British adult
females were used for analyses. A more complete description of
ALSPAC can be found in the ALSPAC section below.Ethical Approval
Ethical approval for the use of cohorts from dbGaP was obtained
from the Institutional Review Board (IRB) of both Boston Chil-
dren’s Hospital and the Broad Institute of Harvard andMIT. Ethical
approval for the use of the 1958 British Birth Cohort was obtained
from the South East Multicentre Research Ethics Committee (SE-
MREC). Ethical approval for the use of ALSPAC was obtained
from the ALSPAC Ethics and Law Committee and the Local
Research Ethics Committees.Quality Control
We filtered out samples that have ambiguous or incorrect gender,
SNPs that have >5%missing rate, samples that have>2%missing
SNPs, SNPs that have minor allele frequencies < 1%, and samples
that have extreme heterozygosity (54 SD). The SNP annotations
for chromosome and base-pair positions were set to the coordi-
nates of hg19 (GRCh37) via the liftOver tool.20 Pairwise IBD/IBS
were calculated and individuals that have excessive matching
with other individuals were removed. A filter of PI_HAT > 0.125
was used for ALSPAC. For all other cohorts, the threshold was set
at PI_HAT > 0.05. Principal components analysis was performed015
with SMARTPCA21 and each study was projected onto HapMap
v.322 space. Samples that did not cluster with the expected
HapMap population were removed. SNPs that have excessive plate
effects (p < 1 3 107) were dropped. For samples that are of Euro-
pean ancestry, SNPs that had excessive deviation from Hardy-
Weinberg equilibrium (p < 1 3 107) were also dropped. Individ-
uals who had no records of sitting height, height, age, or BMI or
had very extreme sitting height ratios (SHR Z score > 4 SD or
SHR Z score < 4 SD) were also removed. The QC protocol was
performed with PLINK23 (v.1.07) and custom R and PERL scripts.Genotype Phasing
For ARIC, CHS, CARDIA, FHS, and ALSPAC, the genotypes were
phased with SHAPEIT2 (v.2.644)24 and imputed with IMPUTE2
(v.2.3).25 For B58C, the genotypes were phased with MACH24
and imputed with Minimac.25Genotype Imputation
The imputation for all cohorts was performed with a 1000 Ge-
nomes version 1 phase 3 reference panel26 containing 379 Euro-
peans, 246 Africans and African Americans, 286 Asians, and 181
Latin Americans. The imputation panel consists of approximately
22million variants (SNPs and indels). For the X chromosome, only
the non-pseudo autosomal region was imputed. The phasing and
imputation were done separately for males and females for the X
chromosome.ALSPAC
Description of Study Numbers
ALSPAC recruited 14,541 pregnant women resident in Avon, UK
with expected dates of delivery 1st April 1991 to 31st December
1992. 14,541 is the initial number of pregnancies for which the
mother enrolled in the ALSPAC study and had either returned at
least one questionnaire or attended a ‘‘Children in Focus’’ clinic
by 19/07/99. Of these initial pregnancies, there were a total of
14,676 fetuses, resulting in 14,062 live births and 13,988 children
who were alive at 1 year of age. We used only the enrolled adult
mothers that had data on sitting height, height, and bodymass in-
dex. After filtering away individuals that were not genotyped or
were removed after going through the quality-control pipeline,
there was a final tally of 3,351 individuals.
Quality Control and Preparation
Centre National de Ge´notypage (CNG) carried out DNA genotyp-
ing on the Illumina human660W-quad array and genotypes were
called with Illumina GenomeStudio. PLINK (v.1.07) was used to
carry out quality-control measures on an initial set of 10,015 sub-
jects and 557,124 directly genotyped SNPs. SNPs were removed if
they displayed more than 5% missingness or a Hardy-Weinberg
equilibrium p value of less than 106. Additionally, SNPs with a
minor allele frequency of less than 1% were removed. Samples
were excluded if they displayed more than 5% missingness or
had indeterminate X chromosome heterozygosity or extreme
autosomal heterozygosity. Samples showing evidence of popula-
tion stratification were identified by multidimensional scaling of
genome-wide identity by state pairwise distances with the four
HapMap populations as a reference, and then excluded. Cryptic
relatedness was assessed with a PI_HATof more than 0.125, which
is expected to correspond to roughly 12.5% alleles shared IBD or a
relatedness at the first-cousin level. Related subjects that passed all
other quality-control thresholds were retained during subsequent
phasing and imputation. 9,048 subjects and 526,688 SNPs passedThe Amthese quality-control filters. We combined 477,482 SNP genotypes
of these subjects with genotype data of a sample of 9,115 children,
removed SNPs with a missingness above 1% due to poor quality
(n ¼ 11,396), and removed a further 321 subjects due to potential
ID mismatches. This resulted in a dataset of 17,842 subjects con-
taining 6,305 duos and 465,740 SNPs (112 were removed during
liftover and 234 were out of HWE after combination). We esti-
mated haplotypes with ShapeIT (v.2.r644), which utilizes related-
ness during phasing.We imputed SNPs against the 1000 Genomes
phase I version 3 integrated set via IMPUTE2 (v.2.3). Analysis was
carried out in SNPtest (v.2.5) including the ten principal compo-
nents of population ancestry from EIGENSTRAT.
Data Dictionary
The ALSPAC study website contains details of all the data that are
available through a fully searchable data dictionary (see Web
Resources).
Overall European Ancestry in African-American
Individuals
Overall European admixture (ARIC, CARDIA, and CHS) was calcu-
lated by SMARTPCA from the CEU and YRI samples of HapMap
v.3.22 CEU individuals were used as proxies of European ancestry
and YRI individuals were used as proxies of African ancestry. The
principal components were calculated using only the CEU and
YRI individuals while projecting them onto the ARIC, CARDIA,
and CHS African Americans. The first principal component
(PC1) was used to calculate the degree of overall European
admixture for each individual. The percentage overall European
admixture was calculated by (IndividualPC1 – YRIPC1)/(CEUPC1 –
YRIPC1) 3 100%, where IndividualPC1 is PC1 for each individual
and CEUPC1 and YRIPC1 are the mean PC1 values for the CEU
and YRI individuals, respectively.
SHR Phenotype for Comparison between European
and African Americans
Both European-American and African-American individuals from
ARIC, CARDIA, and CHS were pooled together and the SHR was
calculated by taking the sitting height divided by overall height.
SHR residuals were obtained by performing linear regression of
SHR against overall height, age, gender, BMI, and cohort as cova-
riates. The SHR Z scores were then obtained by taking the resulting
residuals divided by the estimated standard deviation of the resid-
uals. This was performed with custom R scripts.
SHR Phenotype for GWAS and GCTA-REML Analysis
SHR was calculated by taking the sitting height divided by overall
height. The SHR residuals were obtained by performing linear
regression of SHR against overall height, age, gender, and BMI as
covariates separately for each cohort. For the ARIC, CARDIA,
and CHS cohorts, this was performed separately for the African
Americans and European Americans. For the African Americans,
SHR was also adjusted for overall European ancestry by including
it as a covariate. For ALSPAC, the top ten principal components
were included as covariates to adjust for population stratification.
For the other cohorts, only the components that were nominally
significant (p < 0.05) with SHR were included as covariates to
adjust for population stratification. The SHR Z scores were then
obtained by taking the resulting residuals divided by the estimated
standard deviation of the residuals. The final phenotype for each
cohort/group was then obtained by rank-based inversed normali-
zation. This was performed with custom R scripts.erican Journal of Human Genetics 96, 695–708, May 7, 2015 697
Determining Overall Height Phenotype
The height residuals were obtained by performing linear regres-
sion of height against age and gender and BMI as covariates sepa-
rately for each of the cohorts. Additionally, the data were analyzed
separately for African Americans and European Americans. For
the African-American cohorts, we also adjusted for overall Euro-
pean ancestry by including it as a covariate. Among the top ten
principal components, the components that were nominally sig-
nificant (p < 0.05) were also included as covariates to adjust for
population stratification. The height Z scores were then obtained
by taking the resulting residuals divided by the estimated standard
deviation of the residuals. The final phenotype for each cohort
group was then obtained by rank-based inversed normalization.
This was performed with custom R scripts.
GCTA-REML Analysis
We used the GCTA software27 to calculate the genetic relationship
matrix separately for each chromosome by combining the 3,545
African-American individuals from the ARIC, CARDIA, and CHS
cohorts. We also performed the same calculations by combining
the 11,943 European-American individuals from the ARIC,
CARDIA, and CHS cohorts. We used genome-wide autosomal
SNPs that were well imputed (INFO > 0.8) in all the African-Amer-
ican and European-American cohorts resulting in a total of
10,250,422 and 6,655,203 SNPs for each ancestry group, respec-
tively. We then merged the genetic relationship matrix calculated
for each chromosome to obtain a global genetic relationship ma-
trix for both the African-American and European-American
groups. We then performed GCTA-GREML analysis to estimate
the variance explained by the SNPs for both ancestry groups
with SHR as well as overall height.
Genome-wide Association Study
The associations were performed with the SHR phenotype as the
outcome variable (see above). Only unrelated individuals were
used, i.e., no pair of individuals has PI_HAT > 0.05. The associa-
tion for the imputed variants with SHR was performed by a linear
regression with either PLINK23 (v.1.07) or SNPtest28 (v.2.5). SNPs
that were imputed poorly were discarded (INFO < 0.6). The asso-
ciation results for each cohort were meta-analyzed together via
METAL29 with genomic control correction. Variants on the X
chromosome were analyzed separately between males and fe-
males and meta-analyzed together via METAL.29 For sex-specific
analysis, males and females were separately analyzed via
METAL.29
Enhancer Enrichment Test
The SNPs (Table S2) were mapped from hg18 to hg19 coordinates
via the UCSC liftOver tool.20 For each SNP set, 2,000 sets of
matched SNPs were obtained via SNPsnap with its default set-
tings. These matched SNPs were matched for frequency, LD,
and gene proximity. Proxy SNPs for each SNP set were also
identified with PLINK23 based on LD (r2 > 0.5) between SNPs
(%500 kb) in the European (CEU, GBR, TSI) populations in the
1000 Genomes Phase 1 data.26 Next, the set of permissive en-
hancers defined by the FANTOM5 project30 were used to screen
for enhancer regions that overlap at least one SNP or its proxies
in each SNP set. The enhancer enrichment p value was then
calculated by taking the proportion of matched SNP sets that
contain equal or higher number of enhancers compared to the
observed SNP sets.698 The American Journal of Human Genetics 96, 695–708, May 7, 2Comparison with Known Height-Associated Loci
We obtained the 697 SNPs shown to be robustly associated with
overall height2 (p< 53 108) and analyzed the summary statistics
of SHR from a GWAS of 21,590 individuals of European ancestry.
We filtered out SNPs that were either not present in the GWAS or
failed imputation (INFO < 0.6) in any of the individual cohorts,
which resulted in 670 SNPs. We performed conditional and joint
GWAS31 for the 670 SNPs from the GWAS summary statistics of
SHR from linkage-disequilibrium (LD) estimates calculated from
174CEU individuals fromHapMapv.2.22We then tabulated the ef-
fect sizes and p values for the conditional and joint GWAS for both
height and SHR with respect to the height-increasing allele (Table
S1). The QQ plots and 95% confidence intervals were generated
with custom R scripts. For the symmetrical analysis, we obtained
725 SNPs that were significantly associated (p < 5 3 105)
with SHR from a GWAS of 21,590 individuals of European
ancestry. We pruned away SNPs that were in strong LD (r2 > 0.1)
by using 174 CEU individuals from HapMap v.2, which resulted
in 70 SNPs.
Pathway/Gene-set Enrichment Analysis via DEPICT
A comprehensive pathway/gene-set enrichment and tissue/cell
type analysis was performed by applying a new method,
Data-Driven Expression Prioritized Integration for Complex
Traits (DEPICT),32 which has been recently applied to several
studies.2,33–36 DEPICT performs gene set enrichment analysis by
testing whether genes in GWAS-associated loci are enriched for
reconstituted versions of known molecular pathways (jointly
referred to as reconstituted gene sets). The reconstitution is accom-
plished by identifying genes that are co-regulated with other genes
in a given gene set based on a panel of 77,840 gene expression mi-
croarrays.37 Genes that are found to be transcriptionally co-regu-
lated with genes from the original gene set are added to the gene
set and thus the reconstitution. Several types of gene sets were
reconstituted: 5,984 protein molecular pathways derived from
169,810 high-confidence experimentally derived protein-protein
interactions,38 2,473 phenotypic gene sets derived from 211,882
gene-phenotype pairs from the Mouse Genetics Initiative,39 737
Reactome database pathways,40 184 Kyoto Encyclopedia of Genes
and Genomes (KEGG) database pathways,41 and 5,083 Gene
Ontology database terms.42 In total, 14,461 gene sets were assessed
for enrichment in genes in associated regions. DEPICT also facili-
tated tissue and cell type enrichment analysis by testing whether
the genes in associated regions were highly expressed in any of
209 MeSH annotations for 37,427 microarrays on the Affymetrix
U133 Plus 2.0 Array platform.Results
GCTA-GREML Analysis to Determine Heritability
of SHR
We performed GCTA-GREML analysis12 to estimate the
variance explained by the autosomal SNPs from 3,545 Af-
rican Americans and 11,943 European Americans by using
unrelated individuals from the ARIC,13 CHS,15 CARDIA,16
and FHS17 cohorts. The results show that SHR is highly
heritable; the phenotypic variance explained by the auto-
somal SNPs is estimated to be 0.38 (95% CI: 0.22–0.55;
p ¼ 4.96 3 106) and 0.26 (95% CI: 0.21–0.31; p ¼
1.92 3 1024) for African Americans and European015
Table 1. Estimation of Phenotypic Variance of SHR Explained by
Genetic Relationships from Autosomal SNPs
Phenotype No. of SNPs h2 (SE) LRT p Value
African Americans (n ¼ 3,545)
SHR 10,250,422 0.387 (0.0845) 19.53 4.96 3 106
Height 10,250,422 0.768 (0.0780) 84.79 1.66 3 1020
European Americans (n ¼ 11,943)
SHR 6,655,203 0.26 (0.0267) 102.73 1.92 3 1024
Height 6,655,203 0.449 (0.0265) 322.84 1.74 3 1072
European-American Males (n ¼ 5,477)
SHR 6,655,203 0.366 (0.0552) 46.81 3.92 3 1012
Height 6,655,203 0.485 (0.0550) 83.54 3.11 3 1020
European-American Females (n ¼ 6,466)
SHR 6,655,203 0.188 (0.0454) 19.15 6.05 3 106
Height 6,655,203 0.454 (0.0465) 100.85 4.96 3 1024
The results from GCTA-REML analysis performed on both African- and Euro-
pean-American individuals for SHR as well as overall height using autosomal
variants successfully imputed (INFO > 0.8) in all cohorts.Americans, respectively (Table 1). We also tested overall
height: the phenotypic variance is estimated to be 0.77
(95% CI: 0.62–0.92; p ¼ 1.66 3 1020) and 0.45 (95% CI:
0.4–0.5; p¼ 1.743 1072) for African Americans and Euro-
pean Americans, respectively (Table 1). The variance ex-
plained for European Americans on overall height is
similar to what was previously estimated.2,43
We further investigated gender-specific heritability of
SHR by performing GCTA-GREML analysis separately on
European-American males (n ¼ 5,477) and European-
American females (n ¼ 6,466). The results show that SHR
is significantly more heritable in males than in females;
the phenotypic variance explained for males is estimated
to be 0.37 (95% CI: 0.26–0.47; p ¼ 3.92 3 1012) whereas
for females, it is estimated to be 0.188 (95% CI: 0.10–0.28;
p ¼ 6.05 3 106) (Table 1). Overall height showed no sig-
nificant gender-specific heritability.
Comparing SHR between African and European
Americans
We tested whether SHR differs across populations as previ-
ously reported.11 We used the ARIC,13 CARDIA,16 and
CHS15 cohorts because they include both African Ameri-
cans and European Americans, resulting in a total sample
size of 11,230 European Americans and 3,545 African
Americans. We observed that African Americans have
lower sitting heights than European Americans (Figures
1A–1C): SHR is 1.09 SD lower in African Americans than
European Americans (Figure 1D), consistent with earlier
studies.
To address whether genetic factors could explain the
basis for the SHR difference between populations, we
tested whether the degree of European admixture in Afri-
can Americans is correlated with SHR because AfricanThe AmAmericans have variable amount of European admixture,
with a mean of about 20%.44,45 If genetic factors con-
tribute to the difference between populations, the degree
of overall European admixture within African Americans
should be positively correlated with SHR. We observed
a very strong correlation between overall European
admixture and SHR in the African-American individuals
(Figure 2); on average, a 1% increase in European admix-
ture is correlated with a 0.0166 SD increase in SHR (p ¼
8.23 3 1027). This result can explain most if not all of
the SHR difference between African Americans and Euro-
pean Americans, suggesting that the basis for this differ-
ence is mainly genetic.
GWASs of SHR in African Americans and European
Americans
To test for specific genetic loci associated with SHR, we
performed genome-wide association of SHR on imputed
genotypes of the 3,545 African-American individuals
from ARIC,13 CARDIA,16 and CHS15 cohorts. A single lo-
cus, rs10736877, reached genome-wide significance (p ¼
2.03 3 108) (Table 2; Figures 3 and S1). rs10736877 is a
common variant that is directly genotyped (allele fre-
quency ¼ 51%, effect size ¼ 0.13 SD) and is not in
strong LD with its neighbors and thus none of its neigh-
bors show significant associations with SHR. rs10736877
is upstream of C10orf90, the function of which is still un-
known. Thus, more samples are required to confirm
whether rs10736877 is truly associated with SHR in Afri-
can Americans.
We also performed genome-wide association of sitting
height ratio (SHR) in a total of 21,590 individuals of Euro-
pean ancestry (ARIC,13 CARDIA,16 CHS,15 FHS,17 B58C,18
and ALSPAC19). We identified five independent loci reach-
ing genome-wide significance (p < 5 3 108) (Table 2; Fig-
ures 4 and S2). Of the five lead SNPs, two (rs6931421 and
rs882367) are in strong LD with variants known to be
significantly associated with overall height.1,2 Interest-
ingly, rs1722141 is in the IGFBP3 (MIM 146732) locus,
which has different SNPs significantly associated with
overall height (Table 2); rs1722141 is not itself associated
with height and is not in LD with the height-associated
SNPs. The remaining two loci (rs140449984 and
rs228836) have not been associated with overall height.
Because SHR is significantly different between men
and women and their overall heritability were shown to
be significantly different, we reanalyzed the European
ancestry genome-wide association data for SHR sepa-
rately for females (n ¼ 12,965) and males (n ¼ 8,625).
Although we did not find any additional significant loci
for the female-specific analysis (Figures 5 and S3), two
new loci (rs34638952, rs35832626) reached genome-
wide significance (p < 5 3 108) in the male-specific
analysis (Table 2; Figures 6 and S4). One of these,
rs35832626, has also been shown to be significantly asso-
ciated with overall height, but not in any gender-specific
manner2 (Table 2).erican Journal of Human Genetics 96, 695–708, May 7, 2015 699
Figure 1. Comparing the Distribution
of SHR between European Americans
and African Americans
Plots of sitting height and height of indi-
viduals, both European Americans and
African Americans, from combining the
ARIC, CARDIA, and CHS cohorts. Red
points indicate individuals of African
ancestry; blue points indicate individuals
of European ancestry.
(A) Values of sitting height and height in
centimeters.
(B)Values of SHRandheight in centimeters.
(C) Values of SHR Z scores (adjusted for
height, sex, BMI, age, and cohort) and
height in centimeters.
(D) The histograms of the SHR Z scores of
African Americans (red line) and European
Americans (blue line). The dotted horizon-
tal line indicates the mean difference (in
standard deviation units) between the
two distributions.Comparison with Known Height-Associated Loci
We examined the association statistics of SHR for the SNPs
that were reported to be significantly associated with over-
all height. Among the 697 height-associated SNPs, onlyFigure 2. Association of Global European Admixture with SHR
in African-American Individuals
The association of global European admixture (x axis) with SHR
(y axis) for African-American individuals in the ARIC, CARDIA,
and CHS cohorts (n ¼ 3,545). The correlation (red line) obtained
from linear regression is shown with the corresponding effect
size (b), standard deviation, p value, and r2 (inset).
700 The American Journal of Human Genetics 96, 695–708, May 7, 2015670 SNPs were robustly imputed
(INFO > 0.6) in all of our cohorts.
We performed conditional and joint
GWASs31 for the 670 SNPs from the
GWAS summary statistics of SHR. We
tabulated the effect sizes and p valuesfor both height and SHR with respect to the height-
increasing allele (Table S1). We observed a significant
enrichment of height-associated SNPs that were also nomi-
nally significant with SHR (p < 0.05). A total of 130 SNPs
reached nominal significance whereas only 33.5 were ex-
pected under the null hypothesis (p ¼ 1.16 3 1060)
(Figure 7; Table S2). This result indicates that many of these
130 SNPs have a disproportionate effect on the long bones
or spine/head lengths to cause a change not only in SHR,
but also in overall height. Among these 130 SNPs, 71 of
them had the height-increasing allele predicted to decrease
SHR (SNPlongbones), which indicate that they act dispropor-
tionately on the long bones, whereas 59 had the height-
increasing allele predicted to increase SHR (SNPheadspine),
which indicate that they act disproportionately to affect
head or spine length.
We further performed a symmetric analysis and inves-
tigated the SNPs that were associated with SHR (p < 5 3
105) for their association with overall height. After
pruning for LD, we obtained 70 such SNPs. Of these 70
SNPs, 32 were nominally significant (p < 0.05) for overall
height whereas only 3.5 were expected under the null
hypothesis (p ¼ 3.07 3 1023). Of these 32 SHR-
increasing alleles, 14 were associated with increased
height and 18 were associated with decreased height
(Table S3).
Enhancer Enrichment Analysis
We analyzed the genome-wide significant SNPs (p < 5 3
108) to determine whether there are any overlaps with
known enhancer regions. We used the set of permissive
Table 2. Genome-wide Significant SNPs




rs10736877 chr10: 128,373,707 A/G 0.51 0.1311 (0.0234) 2.03 3 108 C10orf90
European Ancestry
rs6931421 chr6: 80,880,138 T/G 0.68 0.0586 (0.0103) 1.45 3 108 BCKDHB
rs1722141 chr7: 46,016,662 A/G 0.22 0.0667 (0.0121) 3.31 3 108 IGFBP3
rs882367 chr17: 59,494,574 C/T 0.33 0.0778 (0.0104) 8.42 3 1014 TBX2
rs140449984 chr18: 8,321,896 T/TAGA. 0.0747 0.1043 (0.0188) 2.91 3 108 PTPRM
rs228836 chr20: 50,065,648 G/A 0.41 0.0608 (0.0099) 8.48 3 1010 NFATC2
Male-Specific
rs35832626 chr2: 24,054,647 T/C 0.41 0.0902 (0.0159) 1.27 3 108 ATAD2B
rs34638952 chr17: 27,537,410 A/T 0.64 0.0906 (0.0159) 1.12 3 108 MYO18A
The table shows the variants that reached genome-wide significance (p < 5 3 108) when tested for their association with SHR.
ahg19 annotation.
bCandidate gene within the locus.and robust enhancers as defined by the FANTOM5 proj-
ect.30 We obtained the genomic region surrounding the
lead SNPs by taking the other SNPs significant for SHR
(p < 5 3 106) spanning the region (Table S4). The SNPFigure 3. GWAS of SHR of African Americans
The GWAS results of SHR of African-American individuals (n ¼ 3,545
and their relative positions of each variant tested and the y axis in
that reached genome-wide significance is also shown. The horizontal
(p < 5 3 108).
The Amrs10736877 found to be genome-wide significant from Af-
rican Americans had no other SNPs in LD spanning the re-
gion and was dropped from this analysis. Among the seven
remaining genome-wide significant loci, six overlapped) shown as a Manhattan plot. The x axis marks the chromosomes
dicates the –log10 p value. The candidate gene within the locus
dashed line represents the threshold of genome-wide significance
erican Journal of Human Genetics 96, 695–708, May 7, 2015 701
Figure 4. GWAS of SHR of Individuals with Ancestry from Europe
The GWAS results of SHR of individuals with ancestry from Europe (n ¼ 21,590) shown as a Manhattan plot. The x axis marks the
chromosomes and their relative positions of each variant tested and the y axis indicates the –log10 p value. Candidate genes within
loci that reached genome-wide significance are also shown. The horizontal dashed line represents the threshold of genome-wide signif-
icance (p < 5 3 108).with at least one known permissive or robust enhancer re-
gion (Table S5).
Next, we investigated the 130 height-associated SNPs
that were nominally significant (p < 0.05) for SHR. Using
a randomized permutation procedure, we tested whether
the genomic regions surrounding these 130 SNPs have
significant enrichment with the set of permissive en-
hancers as defined by the FANTOM5 project.30 We also
tested the remaining 540 height-associated SNPs that
were not nominally significant for SHR (p > 0.05) in
the same way. We observed that although both groups
of SNPs had significant enrichment for enhancer regions
(p < 0.05), the 130 SNPs are more significantly associ-
ated (p ¼ 0.0005) with enhancer regions than the 540
SNPs (p ¼ 0.003) (Table S6). We further divided the
130 SNPs into the 71 SNPlongbones and 59 SNPheadspine
SNPs and tested them separately for enrichment of
enhancer regions. Again, although we observed that
both the SNPlongbones and SNPheadspine SNPs were signifi-
cantly enriched for enhancer regions (p < 0.05), the
SNPlongbones showed more significant enrichment (p ¼
0.0045) than the SNPheadspine SNPs (p ¼ 0.0465) (Table
S6). These results suggest that there is more overlap
with annotated regulatory regions for height-associated
SNPs that are also associated with SHR, especially those702 The American Journal of Human Genetics 96, 695–708, May 7, 2that were predicted to act disproportionately on the
long bones (SNPlongbones).
Pathway and Tissue Enrichment Analysis by DEPICT
We used a recently available method, Data-Driven Expres-
sion Prioritized Integration for Complex Traits (DEPICT),32
to analyze the various groups of SNPs. We first used the list
of SNPs that were significant from the earlier GWAS of
21,950 individuals of European ancestry. Because there
were only five genome-wide significant SHR loci, which
is too few loci to utilize DEPICT, we used a more liberal sig-
nificance threshold (p < 5 3 106), resulting in 21 distinct
genomic loci (Table S7). Interestingly, although there was
no significant tissue enrichment (Table S9), a single
pathway/gene set, labeled as ‘‘short tibia’’ (MGI MP:
0002764) was significantly enriched (p¼ 5.463 108; false
discovery rate [FDR] < 0.05) (Table S8). With just these 21
loci, DEPICT also successfully prioritized (FDR < 0.05) a
candidate causal gene in three of these loci (NSD1 [MIM
606681], DMP1 [MIM 600980], and IBSP [MIM 147563])
(Table S10).
We next analyzed the set of 130 height-associated SNPs
that were nominally associated with SHR (Table S2). We
also separately analyzed a set of 130 height-associated
SNPs that have the least significant SHR p values (Table015
Figure 5. Female-Specific GWAS of SHR of Individuals with Ancestry from Europe
The GWAS results of SHR using only the female individuals with ancestry from Europe (n ¼ 12,965) shown as a Manhattan plot. The x
axis marks the chromosomes and their relative positions of each variant tested and the y axis indicates the –log10 p value. The candidate
gene within the locus that reached genome-wide significance is also shown. The horizontal dashed line represents the threshold of
genome-wide significance (p < 5 3 108).S11). We used both sets of SNPs as inputs and analyzed
them with DEPICT. For the 130 SNPs that were nominally
associated with SHR, DEPICT reported a substantial num-
ber (>500) of pathway/gene sets that were significantly
enriched (FDR < 0.05) (Table S12). Many of these gene
sets had belonged to pathways involved in bone develop-
ment, e.g., ‘‘abnormal rib morphology,’’ ‘‘chondrocyte dif-
ferentiation,’’ ‘‘abnormal skeleton morphology,’’ etc. The
‘‘short tibia’’ gene set found previously was also signifi-
cant. There were also a number of cell/tissue types (ten
types) that showed significant enrichment (FDR < 0.05)
(Table S13). These cell/tissue types included the tissues
that are known to be broadly involved in skeletal growth,
like cartilage, chondrocytes, and spine. In contrast, the
130 SNPs least associated with SHR had much fewer
significant pathways or gene sets that are directly associ-
ated with skeletal or bone development and appear
to be more strongly associated with pathways involved
in early development, e.g., ‘‘embryonic growth retarda-
tion,’’ ‘‘decreased embryo size,’’ ‘‘decreased cell prolifera-
tion,’’ etc. (Table S14). These 130 SNPs also showed signif-
icant enrichment in some cell/tissue types (three types)
(FDR < 0.05), but none of those directly involved in
skeletal growth, i.e., cartilage, chondrocytes, and spine,
showed significant enrichment (Table S15). By comparingThe Amthe top 30 pathways or gene sets discovered from either
set of SNPs, we demonstrate that the height-associated
SNPs nominally associated with SHR are tied more with
pathways involved in skeletal, bone, or cartilage develop-
ment whereas the height-associated SNPs least associated
with SHR are tied more to pathways involved in embry-
onic development (Figure 8).
Finally, we analyzed the 71 SNPlongbones and 59
SNPheadspine SNPs separately with DEPICT. The
SNPlongbones SNPs yielded a number of pathways/gene
sets (>30) that were significant (FDR < 0.05) (Table
S16). Although the number of significant pathways/
gene sets were much smaller than those obtained from
using all the 130 SNPs, the results were similar, i.e., the
significant gene sets generally belonged to pathways
involved in bone development like ‘‘abnormal rib
morphology,’’ ‘‘skeletal system development,’’ and ‘‘short
ribs.’’ There were also three cell/tissue types that were
enriched, i.e., ‘‘cartilage,’’ ‘‘mesenchymal stem cells,’’
and ‘‘osteoblasts’’ (FDR < 0.05) (Table S17), implicating
the tissues involved in cartilage and bone development.
In contrast, there were no significant results (FDR <
0.05) from analyzing the SHRheadspine SNPs (Tables S18
and S19). This suggests that the genes disproportionately
affecting the long bones are more tied to known skeletalerican Journal of Human Genetics 96, 695–708, May 7, 2015 703
Figure 6. Male-Specific GWAS of SHR of Individuals with Ancestry from Europe
The GWAS results of SHR using only the male individuals with ancestry from Europe (n ¼ 8,625) shown as a Manhattan plot. The x axis
marks the chromosomes and their relative positions of each variant tested and the y axis indicates the –log10 p value. Candidate genes
within loci that reached genome-wide significance are also shown. The horizontal dashed line represents the threshold of genome-wide
significance (p < 5 3 108).growth pathways than are genes disproportionately
affecting the head/spine, although this could be due to
having fewer SNPheadspine loci than SNPlongbones loci.
Nonetheless, these results demonstrate that the height-
associated SNPs can be stratified into different biological
groups by examining their respective effects on SHR.Discussion
Unlike overall height, body proportion or sitting height ra-
tio (SHR) has not beenwell studied and less is known about
its underlying genetics. Here, we have provided evidence
that SHR is heritable and we have identified loci that are
significantly associated with SHR. We also showed that
the lower SHR in African-ancestry populations is consistent
with an effect of genetic factors. However, the GWAS per-
formed on African-American samples did not identify loci
that either explains much of the heritability of SHR nor
much of the difference between European- and African-
ancestry populations. These results suggest that the differ-
ence in SHR is polygenic, i.e., due to many loci.
The results from the GWAS of individuals of European
ancestry yielded more genome-wide significant results,
probably because of the larger number of samples. The
most significant locus (rs882367) has been shown to be704 The American Journal of Human Genetics 96, 695–708, May 7, 2significantly associated with overall height.1 Although
the most plausible candidate gene in this locus (TBX2
[MIM 600747]) has been demonstrated to affect heart
development,46,47 it has also been suggested to cause
limb abnormalities and skeletal malformations.48,49
Another significant locus (rs1722141), although not signif-
icantly associated with overall height, contains multiple
SNPs, not correlated to rs1722141, that are strongly associ-
ated with height. The likely gene underlying this locus
(IGFBP3 [MIM 146732]) is known to bind to and modulate
IGF by increasing IGF half-life and inhibiting or potenti-
ating IGF binding to the IGF receptor,50 which has been
directly tied to skeletal growth.51 The SNPs that are associ-
ated with SHR, but not overall height, have also been
shown to be significantly correlated with circulating levels
of IGFBP3,52 suggesting that circulating IGFBP3 levels
might influence body proportion.
Some of the SNPs that showed suggestive significance
(p < 5 3 106) are in loci with genes underlying Mende-
lian causes of growth disorders and/or skeletal dysplasias
that are known to affect body proportion. One example,
rs2011077 (p ¼ 2.52 3 107), is near NSD1, a known
cause of Sotos syndrome (MIM 117550), which is charac-
terized by extreme overgrowth in childhood, large head
size, and advanced bone age. Individuals affected with
Sotos syndrome have a decreased upper to lower body015
Figure 7. QQ Plot of the 670 Height-Associated SNPs with SHR
The plot shows the observed –log10 p values of SHR (y axis) for the
670 height-associated SNPs and compare them with the expected
–log10 p values (x axis) under the null hypothesis. The red line is
the trend line under the null hypothesis and the dashed lines indi-
cate the 95% confidence interval under the null hypothesis.segment ratio as compared to age- and gender-matched
controls.53
We also demonstrated that SHR is a useful tool to
understand the underlying biology of height-associated
loci. Although height and SHR are orthogonal traits, we
showed that there are significant overlaps between the
loci affecting SHR and the loci affecting overall height.Figure 8. Pathway Analysis by DEPICT of Height-Associated SNPs
Comparing the top 30 gene sets obtained by DEPICT for the 130 kn
(SHR-positive gene set) as well as the 130 known height-associated S
necting two gene sets indicates that the gene sets have a Pearson co
The AmHeight-increasing alleles that cause a reduction in SHR
have to have disproportionate effect such that the increase
in long bone length is relatively larger than the increase
in the spine and/or head length. In contrast, height-in-
creasing alleles that cause an increase in SHR have a rela-
tively larger effect on the spine and/or head. From the
pathway analysis by DEPICT, we have shown that the
loci affecting height disproportionately through the long
bones (SNPlongbones) are involved in fundamental processes
of bone and cartilage development whereas loci in the
other sets are less clearly connected to these processes.
Recent work has raised the possibility that adjusting one
trait for a highly correlated covariate can lead to false-pos-
itive ‘‘mirror’’ associations at variants that are strongly
associated with the covariate.54 This phenomenon will
cause such variants to be associated with the trait but
have a direction of effect that is opposite of the covariate.
This phenomenon does not explain our result because our
SHR associations are divided between SNPs that are associ-
ated with increased and decreased height. Furthermore,
SHR is only weakly correlated with height and not all
height-associated SNPs at genome-wide significance are
associated with SHR.
Overall, this study is a large-scale whole-genome experi-
ment to address the underlying genetic basis for differ-
ences in body proportion by SHR. We uncovered several
loci that are significantly associated with SHR and showed
that many loci associated with height also alter SHR.
These results suggest that SHR is also polygenic and that
further studies of larger sample sizes are required to
explain the full genetic spectrum of SHR. Finally, we
demonstrated that SHR can be used as a prism (Figure 9)
to partition the height-associated loci into those that affectown height-associated SNPs also nominally associated with SHR
NPs least associated with SHR (SHR-negative gene set). A line con-
rrelation coefficient > 0.6.
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Figure 9. SHR as a Prism to Dissect the
Height-Associated SNPs into Functional
Classes
This diagram illustrates the use of an
orthogonal phenotype like SHR to parti-
tion the known variants associated with
overall height into various functional
classes (head/spine, long bones, and
balanced).the head/spine, the long bones, or have no effect on SHR
and showed that different groups of loci are enriched for
different pathways and tissue types. This suggest that in
general, the use of orthogonal but related phenotypes
can be used as a tool to dissect the variants into different
functional classes so as to better understand the biological
mechanism underlying the trait or disease.Supplemental Data
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